English
Home > Products > Afatinib diMaleate API

China Afatinib diMaleate API Factory

Our rewards are lessen selling prices,dynamic sales team,specialized QC,solid factories,high quality services for Afatinib diMaleate API,CAS NO 850140-73-7,850140-73-7,Afatinib diMaleate, "Making the Merchandise of Significant Quality" could be the eternal goal of our firm. We make unremitting endeavours to know the aim of "We Will Always Keep in Pace using the Time".
Afatinib diMaleate API, With excellent merchandise, high quality service and sincere attitude of service, we ensure customer satisfaction and help customers create value for mutual benefit and create a win-win situation. Welcome customers all over the world to contact us or visit our company. We are going to satisfy you with our expert service!

Related Products

Hot Products

  • 2,6-Diamino-4,5,6,7-tetrahydrobenzothiazole

    2,6-Diamino-4,5,6,7-tetrahydrobenzothiazole

    Product Name:2,6-Diamino-4,5,6,7-tetrahydrobenzothiazole
    Molecular Formula:C7H11N3S
    Molecular Weight:169.25
    CAS Registry Number:104617-49-4
  • Eslicarbazepine acetate

    Eslicarbazepine acetate

    Product Name:Eslicarbazepine acetate
    Molecular Formula:C17H16N2O3
    Molecular Weight:296.32
    CAS Registry Number;236395-14-5
  • 4-Amino-3-chlorophenol hydrochloride

    4-Amino-3-chlorophenol hydrochloride

    Product Name:4-Amino-3-chlorophenol hydrochloride
    Molecular Formula:C6H7Cl2NO
    Molecular Weight:180.03
    CAS Registry Number:52671-64-4
  • 1-Bromopropane

    1-Bromopropane

    Product Name:1-Bromopropane
    Molecular Formula:C3H7Br
    Molecular Weight:122.99
    CAS Registry Number:106-94-5
  • 2-Pyrazinecarbonitrile, 3,6-difluoro-

    2-Pyrazinecarbonitrile, 3,6-difluoro-

    Product Name:2-Pyrazinecarbonitrile, 3,6-difluoro-
    Molecular Formula:C5HF2N3
    Molecular Weight:141.08
    CAS Registry Number:356783-28-3
  • Acetylcysteine

    Acetylcysteine

    Product Name:Acetylcysteine
    Molecular Formula:C5H9NO3S
    Molecular Weight;163.19
    CAS Registry Number;616-91-1
  • Related Blog
  • Reviews

  • TOP 8 Linezolid intermediate maker

    Sandoo Pharmaceuticals and Chemicals Co.,Ltd was established in 2009, with a creative and active team, located in Ningbo, China. We have been specialized in exporting and importing pharmaceutical intermediates and chemical products as well as API for more than 10 years, covering more than 10 countries.

  • What Is Ursodeoxycholic Acid Used For?

    Ursodeoxycholic acid is a cholelithiant commonly used in the gastroenterology department, and also a cholelithiasis dissolving agent, so it can be used in the treatment of gallstones under normal circumstances, on the premise...

  • Differences Between Pharmaceutical Raw Materials, Excipients and Pharmaceutical Intermediates

    In the pharmaceutical industry, there are various names of raw materials, such as pharmaceutical raw materials, pharmaceutical intermediates and pharmaceutical excipients in the process of pharmaceutical production. This article will take everyone to recognize these three concepts.

  • Baloxavir marboxil

    Baloxavir marboxil is used to treat flu symptoms caused by influenza virus in people who have had symptoms for no more than 48 hours. Baloxavir marboxil will not treat the common cold. Baloxavir marboxil is for adults and children who are at least 12 years old and weigh at least 88 pounds (40 kilograms).

  • CAS No. 144689-24-7 Olmesartan Introduction

    Olmesartan is an angiotensin II receptor blocker, widely used for the treatment of hypertension. The Renin-Angiotensin-Aldosterone System (RAAS) plays an importent role in the development and progression of many diseases such as hypertension...

  • FDA approves lorlatinib for second- or third-line treatment of ALK-positive metastatic NSCLC

    On November 2, 2018, the Food and Drug Administration granted accelerated approval to lorlatinib (LORBRENA, Pfizer, Inc.) for patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.

Send Inquiry

Hit enter to search or ESC to close
X
We use cookies to offer you a better browsing experience, analyze site traffic and personalize content. By using this site, you agree to our use of cookies. Privacy Policy
Reject Accept